You are here

  • Home
  • Archive
  • Volume 7, Issue 9
  • UK-based prospective cohort study to anglicise and validate the FACE-Q Skin Cancer Module in patients with facial skin cancer undergoing surgical reconstruction: the PROMISCR (Patient-Reported Outcome Measure in Skin Cancer Reconstruction) study

Article info

Article menu

Download PDFPDF

XML
Patient-centred medicine
Protocol
UK-based prospective cohort study to anglicise and validate the FACE-Q Skin Cancer Module in patients with facial skin cancer undergoing surgical reconstruction: the PROMISCR (Patient-Reported Outcome Measure in Skin Cancer Reconstruction) study

Authors

  • Thomas Dobbs Reconstructive Surgery & Regenerative Medicine Research Group, Institute of Life Sciences, Swansea University Medical School, Swansea, UKWelsh Centre for Burns and Plastics, Morriston Hospital, Swansea, UK PubMed articlesGoogle scholar articles
  • Hayley A Hutchings Department of Health Services Research, Institute of Life Sciences, Swansea University Medical School, Swansea, UK PubMed articlesGoogle scholar articles
  • Iain S Whitaker Reconstructive Surgery & Regenerative Medicine Research Group, Institute of Life Sciences, Swansea University Medical School, Swansea, UKWelsh Centre for Burns and Plastics, Morriston Hospital, Swansea, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Thomas Dobbs; tomdobbs{at}doctors.org.uk
View Full Text

Citation

Dobbs T, Hutchings HA, Whitaker IS
UK-based prospective cohort study to anglicise and validate the FACE-Q Skin Cancer Module in patients with facial skin cancer undergoing surgical reconstruction: the PROMISCR (Patient-Reported Outcome Measure in Skin Cancer Reconstruction) study
BMJ Open 2017;7:e016182. doi: 10.1136/bmjopen-2017-016182

Publication history

  • Received January 30, 2017
  • Revised August 17, 2017
  • Accepted August 22, 2017
  • First published September 24, 2017.
Online issue publication 
January 10, 2022
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/